OMNIPAQUE 240 Drug Patent Profile
✉ Email this page to a colleague
When do Omnipaque 240 patents expire, and when can generic versions of Omnipaque 240 launch?
Omnipaque 240 is a drug marketed by Ge Healthcare and is included in two NDAs.
The generic ingredient in OMNIPAQUE 240 is iohexol. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the iohexol profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OMNIPAQUE 240?
- What are the global sales for OMNIPAQUE 240?
- What is Average Wholesale Price for OMNIPAQUE 240?
Summary for OMNIPAQUE 240
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 98 |
| Clinical Trials: | 25 |
| Patent Applications: | 3,714 |
| DailyMed Link: | OMNIPAQUE 240 at DailyMed |
Recent Clinical Trials for OMNIPAQUE 240
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal | Phase 4 |
| Claire Bourgeois | Phase 4 |
| Fédération des médecins résidents du Québec | Phase 4 |
Pharmacology for OMNIPAQUE 240
| Drug Class | Radiographic Contrast Agent |
| Mechanism of Action | X-Ray Contrast Activity |
US Patents and Regulatory Information for OMNIPAQUE 240
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | OMNIPAQUE 240 | iohexol | SOLUTION;INJECTION, ORAL, RECTAL | 018956-002 | Dec 26, 1985 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ge Healthcare | OMNIPAQUE 240 | iohexol | SOLUTION;INJECTION, ORAL, RECTAL | 020608-001 | Oct 24, 1995 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OMNIPAQUE 240
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ge Healthcare | OMNIPAQUE 240 | iohexol | SOLUTION;INJECTION, ORAL, RECTAL | 018956-002 | Dec 26, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| Ge Healthcare | OMNIPAQUE 240 | iohexol | SOLUTION;INJECTION, ORAL, RECTAL | 018956-002 | Dec 26, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| Ge Healthcare | OMNIPAQUE 240 | iohexol | SOLUTION;INJECTION, ORAL, RECTAL | 018956-002 | Dec 26, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OMNIPAQUE 240
See the table below for patents covering OMNIPAQUE 240 around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 1132901 | AGENT DE CONTRASTAGE AUX RAYONS X A BASE D'ANILINE ET TAMPON DONT LE PH S'ABAISSE AVEC LA TEMPERATURE (ANILINE X-RAY AGENT AND BUFFER WHOSE PH DECREASES WITH TEMPERATURE) | ⤷ Sign Up |
| South Africa | 7903313 | ⤷ Sign Up | |
| Philippines | 10017 | NOVEL IODINATED X-RAY CONTRAST AGENTS | ⤷ Sign Up |
| Israel | 34803 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
